Ml130

DAPI, etoposide, Hoechst, PMA, staurosporine (Sigma); Fugene (Promega), LCL161 (Active Biochem), Mito Tracker Deep Red (Life Technologies), ML-130 (Tocris), Z-VAD-fmk (Gentaur) were used as indicated.

FK565 (heptanoyl-γ-D-glutamyl-L-meso –diamino-pimelyl-D-alanine) was obtained from Fujisawa Pharmaceuticals (Osaka, Japan). H89, SP600125, U0126, pERK (#4370), ERK (#4695), p-p38 (#9215), p38 (#9212) β-Actin (#5125) and phospho-PKA substrate (#9624) antibodies were from Cell Signaling Technology (Boston, MA, USA). Fatty acid-free bovine serum albumin (BSA), ammonium pyrrolidinedithiocarbamate (PDTC) and isoproterenol were from Sigma Aldrich (St. Louis, MO). CAY10499 and CAY10470 were from Cayman Chemicals (Ann Arbor, MI). Myristoylated PKI (14–22) amide and ML130 were from Tocris Bioscience (Bristol, UK). Dulbecco's modified Eagle medium (DMEM), Dulbecco's Phosphate-Buffered Saline (DPBS) and fetal bovine serum (FBS) were from Life Technologies (Burlington, ON, CA). c12-iEDAP and MDP were from Invivogen (San Diego, CA).

Cells were pre-treated with ML130 (5 μM; CID-1088438; Tocris, UK)^{28 (link)}, WEHI-345 (0, 5 or 10 μM)^{29 (link)} or Z-YVAD-fmk (0, 1, 5, and 10 μM; 21874; Merck, Australia) for 1 h prior to stimulation with H. pylori, then maintained in the inhibitor-containing medium throughout the experiments.